clinical trial · NCT04735393
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye DiseaseReproxalap Ophthalmic Solution (0.25%)Placebo ComparatorReproxalap Ophthalmic Solution (0.25%)Placebo Comparator
brief summary
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry Eye Disease
started
Jan 26, 2021
primary completion
Oct 11, 2022
completion
Oct 11, 2022
last updated
Nov 26, 2025
official title
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol